Chin Peter Scott
Chief Medical Officer
Chin Peter Scott has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Sep 9, 2026.
On the most recent filing, Chin Peter Scott is listed as Chief Medical Officer at Denali Therapeutics Inc. Inside the rolling window, Chin Peter Scott reported no open-market purchases and 1 open-market sale totaling $37K in DNLI.
Companies traded
Other insiders at DNLI
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$37K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Chin Peter Scott made?
Chin Peter Scott has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.
Which companies does Chin Peter Scott trade?
Chin Peter Scott has filed SEC Form 4 disclosures for 1 company, including DNLI.
When was Chin Peter Scott's most recent SEC Form 4 filing?
Chin Peter Scott's most recent SEC Form 4 filing on Tracefour is dated Sep 9, 2026.
What is Chin Peter Scott's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Chin Peter Scott is listed as Chief Medical Officer.
What is Chin Peter Scott's total buy and sell value in the current window?
Inside the rolling retention window, Chin Peter Scott bought $0 and sold $37K based on SEC Form 4 filings.
What was Chin Peter Scott's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 1,654 DNLI shares on 2026-09-04, worth $37K, per SEC Form 4 filings.